Share this page!

Paolo Tarantino Profile picture
Twitter logo
Feb 28 • 4 tweets • 3 min read
Proud to contribute to the remarkable scientific journey of #APT, whose 10-year analysis is now published on @TheLancetOncol. Adjuvant TH confirmed outstanding long-term outcomes for patients with small HER2+ breast cancer. Aim for the next decade: biomarker-informed treatments!
Here a thread on the clinical and biomarker findings from this 10-year update: 👇 🧵
Icing on the cake: a great accompanying commentary by Elena Geuna, @curijoey & @FilippoMontemu1

sciencedirect.com/science/articl…
A thousand thanks to @stolaney1 for making this practice changing work possible and for being a constant source of inspiration, to the @RevealGenomics team for the partnership that helped learning from the samples, and to all the patients and researchers involved in this trial.

• • •

Missing some Tweet in this thread? You can try to force a refresh
　

Keep Current with Paolo Tarantino

Paolo Tarantino Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @PTarantinoMD

Paolo Tarantino Profile picture
Mar 1
@TumorBoardTues @drsarahsam 1/24 #TumorBoardTuesday #BreastCancer #OncTwitter
54yo 👩🏻 post-menopausal
HTN
hypothyroidism
FH: aunt with late-onset BC
Germline genetic testing: negative

🔪Dec ‘10 Left lumpectomy + SLNB:
left IDC G2
ER 95%
PgR 10%
HER2-neg (IHC 1+)
Ki67 35%
stage pT2 (25 mm) pN0
Oncotype 32
@TumorBoardTues @drsarahsam 2/24 #TumorBoardTuesday #BCSM

☢️Jan ‘11: TC x 4 ➡️ XRT
Treatment well tolerated, apart from alopecia, G2 fatigue

Summer ‘11 – started letrozole
🔀 Fall ‘11 – switch to exemestane due to G3 arthralgias ➡️ improvement of symptoms

2016 completed 5 years of Aromatase Inhibitor
@TumorBoardTues @drsarahsam 3/24 #TumorBoardTuesday #BCSM

Apr ‘21 – Mild abdo discomfort
🩻CT CAP scan:
liver: 5 lesions, max 15 mm
bone: spine & ribs
enlarged mediastinal lymph nodes
🩸: G1 anemia, normal LFTs, no other abnormality

🔬US-guided liver biopsy:
IDC, grade 2, ER 90%, PR 0%, HER2-0, Ki67 25%
Read 26 tweets
Paolo Tarantino Profile picture
Feb 21
Great idea: time for Elacestrant thread Tuesday! 🧵

But first a reminder: access to paywalled papers from @Annals_Oncology, @ESMO_Open & multiple other affiliated journals is free for @myESMO members, and I could not recommend more to become a member! esmo.org/membership
1/
Endocrine treatment is among the most effective treatment strategies we have for breast cancer. 50 years ago, the approval of the SERD tamoxifen really revolutionized the field, & we still use the drug today.

Yet, no novel ET had been approved for the last 20 years. Until now
2/
Multiple oral SERDs (selective estrogen receptor degraders) are being developed for patients with HR+ MBC. The first to achieve positive phase 3 results was elacestrant, tested in the #EMERALD trial vs. SoC ET (fulvestrant or AI). Primary endpoint -> PFS overall & in ESR1-mut

3/
Read 9 tweets
Paolo Tarantino Profile picture
Nov 14, 2022
T-DXd has shown remarkable activity for treating HER2-positive and HER2-low breast cancers.

However, it may soon expand its reach, and become a treatment option even for HER2-0 tumors.

Here’s the 10 reasons why:
1. Because it works!

The only study that tested T-DXd for treating HER2-0 metastatic breast cancer (the phase 2 DAISY trial) demonstrated a response rate of 30% and a duration of response of 6.8 months. Not bad for being “zero”.

oncologypro.esmo.org/meeting-resour…
2. Because activity of T-DXd in HER2-0 has been also observed in other tumor types.

In DESTINY-Lung01 (T-DXd for HER2-mutant NSCLC), several responses were observed in patients w/ HER2-0 tumors, including the only complete response observed in the trial.

nejm.org/doi/full/10.10…
Read 12 tweets
Paolo Tarantino Profile picture
Jul 20, 2022
@TumorBoardTues @CaterinaSpo 1/16 #TumorBoardTuesday #BreastCancer #OncTwitter

52yo 👩🏻 post-menopausal, no sig comorbidities.
FH: 2 sisters with young onset BC.
Genetic testing: BRCA1+

🔪‘Bilat Mastectomy + left SLNB:

left IDC G3
ER 0%
PgR 0%
HER2 1+ (TNBC)
Ki67 95%

stage pT1c (17 mm) pN0
@TumorBoardTues @CaterinaSpo 2/16 #TumorBoardTuesday

👩🏻 adjuvant TC ➡️ discontinued after 3rd cycle➡️poor tolerance & recurring FN

22 mo. later --> CT: Lt supraclavicular & multi mediastinal LN met, Rt pleural effusion

🔬LN bx: metastasis of TNBC (ER 0%, PgR 0%, HER2 1+, Ki67 81%). PD-L1 CPS: <10%.
@TumorBoardTues @CaterinaSpo 3/16 #TumorBoardTuesday #BCSM

🤨 Which 1L systemic treatment would you choose for a patient with a gBRCA1m and metastatic recurrence of TNBC with the above 👆🏽 characteristics?

@ErikaHamilton9 @FilipaLynce @maryam_lustberg @SusanGKomen @HeekeMd @stolaney1 @barrosolab
Read 16 tweets
Paolo Tarantino Profile picture
May 26, 2022
In ten days, the presentation of DB-04 may redefine the way we classify and treat breast cancer.

Here’s ten HER2-low facts you need to know before attending the ASCO Plenary Session:
1/10 About half of all BCs have HER2-low expression, defined as HER2 IHC 1+ or 2+/ISH-.

The rate of HER2-low tumors depends however on the expression of ER:
- TNBC: 40% HER2-low
- Moderate ER-exp: 45-55% are HER2-low
- Highly ER-exp: >60% are HER2-low

oncologypro.esmo.org/meeting-resour…
2/10 HER2-low expression is not associated with major biologic differences (vs. HER2-0). Most HR+ breast tumors are luminal and most TNBCs are basal-like at PAM50, regardless of HER2-low expression

nature.com/articles/s4152…
Read 11 tweets
Paolo Tarantino Profile picture
May 17, 2022
@TumorBoardTues @HeekeMd @BreastCancerMD1 @BreastCaupdates @breastcancer @SirohiBhawna 1/13 #TumorBoardTuesday #BreastCancer #OncTwitter

48yo♀️, persistent cough, 4cm L breast mass

PMH: Retinal detach

🖥️Many small lung🫁& mediastinal LN mets

Breast💉Bx: G3 IDC, ER 0%, PR 0%, HER2 3+, Ki67 80%

🤔For newly Dxed HR-/HER2+ MBC which 1L systemic Tx would you use❓
@TumorBoardTues @HeekeMd @BreastCancerMD1 @BreastCaupdates @breastcancer @SirohiBhawna 2/13 #TumorBoardTuesday #BreastCancer #OncTwitter

💊Treated with THP➡️PR for 9 months

👉Then,🖥️new lung and LN mets

🤔Which 2L systemic treatment would you recommend for this patient❓
@TumorBoardTues @HeekeMd @BreastCancerMD1 @BreastCaupdates @breastcancer @SirohiBhawna 3/13 #TumorBoardTuesday #BreastCancer #OncTwitter
🧑‍🏫Mini tweetorial 1

✅T-DM1 is an ADC
➡️Trastuzumab conjugated to DM1 through a stable linker

✅T-DM1 became the SOC 2L💊for HER2+ MBC after the EMILIA trial
➡️TDM-1⬆️PFS & OS vs. cape/lapat
➡️mPFS/OS for T-DM1: 9.6mo/30.9mo Image
Read 13 tweets

Did Thread Reader help you today?

Support us! We are indie developers!

This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us on Twitter!

Send Email!

:(